Effect of rosiglitazone and ramipril on macrovasculopathy in patients with type 2 diabetes: needs longer treatment and/or higher doses?

INTRODUCTION: The aim of the study is to investigate whether standard doses of rosiglitazone (4 mg/daily) and ramipril (5 mg/daily) can reverse pre-clinical macrovasculopathy in newly diagnosed never treated type 2 diabetes (T2DM) patients. METHODS: In this randomized, double-blind, placebo-controll...

Descripción completa

Detalles Bibliográficos
Autores principales: Rahman, Sayeeda, Ismail, Aziz Al-Shafi, Ismail, Shaiful Bhari, Naing, Nyi Nyi, Rahman, Abdul Rashid Abdul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262381/
https://www.ncbi.nlm.nih.gov/pubmed/22291490

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262381/
https://www.ncbi.nlm.nih.gov/pubmed/22291490

Ejemplares similares